Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Bemiltenase alfa in Hemophilia: NCT04747964 Clinical Landscape Report 2026
16 October 2026
NCT04747964 clinical landscape for Hemophilia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Survodutide in Fibrosis, Liver: ACTRN12621000080820 Clinical Landscape Report 2026
16 October 2026
ACTRN12621000080820 clinical landscape for Fibrosis, Liver: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Hydroxycarbamide in Anemia, Sickle Cell: NCT04750707 Clinical Landscape Report 2026
16 October 2026
NCT04750707 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pirfenidone in Idiopathic Pulmonary Fibrosis: ACTRN12621000170820 Clinical Landscape Report 2026
16 October 2026
ACTRN12621000170820 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Efruxifermin in Metabolic Dysfunction Associated Steatohepatitis: NCT04767529 Clinical Landscape Report 2026
16 October 2026
NCT04767529 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Recombinant human coagulation factor VIIa (ChiaTai Tianqing) in Hemophilia B: NCT04768699 Clinical Landscape Report 2026
16 October 2026
NCT04768699 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BMS-963272 in Metabolic Dysfunction Associated Steatohepatitis: NCT04766476 Clinical Landscape Report 2026
16 October 2026
NCT04766476 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Survodutide in Metabolic Dysfunction Associated Steatohepatitis: NCT04771273 Clinical Landscape Report 2026
16 October 2026
NCT04771273 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Omesdafexor in Metabolic Dysfunction Associated Steatohepatitis: NCT04773964 Clinical Landscape Report 2026
16 October 2026
NCT04773964 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
XENON XE 129 hyperpolarized in Pulmonary Disease, Chronic Obstructive: NCT04778046 Clinical Landscape Report 2026
16 October 2026
NCT04778046 clinical landscape for Pulmonary Disease, Chronic Obstructive: endpoints, sponsor, phase, geography, readouts, asset context and development whit…
9 min read
Crizanlizumab-TMCA in Anemia, Sickle Cell: CTRI/2021/03/032137 Clinical Landscape Report 2026
16 October 2026
CTRI/2021/03/032137 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CRISPR-SCD-001 in Acute Chest Syndrome: NCT04774536 Clinical Landscape Report 2026
16 October 2026
NCT04774536 clinical landscape for Acute Chest Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.